Search

Your search keyword '"M. Rendina"' showing total 67 results
Start Over Author "M. Rendina" Topic business.industry
Sorry, I don't understand your search. ×
67 results on '"M. Rendina"'

1. Gadolinium theranostics for the diagnosis and treatment of cancer

Author

Amy G. Robertson and Louis M. Rendina

Subjects
Oncology, medicine.medical_specialty, theranostic, Antineoplastic Agents, Gadolinium, 010402 general chemistry, Diagnostic tools, 01 natural sciences, Theranostic Nanomedicine, World health, Neoplasms, Internal medicine, medicine, 0302 Inorganic Chemistry, Humans, cancer, Precision Medicine, photon activation therapy, 0304 Medicinal and Biomolecular Chemistry, 010405 organic chemistry, business.industry, bioinorganic, Cancer, General Chemistry, medicine.disease, 3. Good health, 0104 chemical sciences, neutron capture therapy, Oncology patients, nanoparticles, gadolinium, business, 03 Chemical Sciences
Abstract

According to the World Health Organization (WHO), there were 18.1 million new cancer cases and 9.6 million cancer deaths reported worldwide in 2018. These numbers are expected to rise over the next decade, and the development of new and effective cancer treatments and diagnostic tools is urgently required, particularly for aggressive and intractable malignant cancers such as those of the brain. An exciting field of cancer research involves combining therapeutic and diagnostic tools into a single 'theranostic' platform. The role of theranostics in the personalized management of oncology patients is increasing, as is the demand for new types of theranostic agents. Some of the most promising cancer theranostics exploit the lanthanoid metal gadolinium, an element possessing favourable therapeutic and imaging properties.

Published
2021

5. Development of a model based on case-mix analysis to predict 6-month patient survival after liver transplantation: a multicenter Italian study

Author

Salvatore Gruttadauria, Marco Vivarelli, Fausto Zamboni, S. Ginanni Corradini, L. Lupo, Silvia Martini, L. De Carlis, Stefano Fagiuoli, Ilaria Lenci, Giuseppe Valerio Bianco, Lino Belli, P De Simone, W. Santaniello, Gabriele Spoletini, Pierluigi Toniutto, Renato Romagnoli, L. Mameli, Matteo Cescon, Valerio Giannelli, Michele Colledan, A.W. Avolio, Antonio Benedetti, Quirino Lai, Riccardo Volpes, G.G. Di Costanzo, Giuseppe Maria Ettorre, U Tedeschi, G. Tisone, A. Grieco, Amedeo Carraro, Sherrie Bhoori, Salvatore Agnes, Paola Carrai, Francesco Donato, U. Cillo, P. Burra, A Franco, Andrea Risaliti, Gemma Rossi, V. Nobile, F. Di Benedetto, C. Donato, R. Calia, Marcos A. Rossi, M. Rendina, Marco Spada, Vincenzo Mazzaferro, N. De Maria, Avolio, A, Lai, Q, Franco, A, Bianco, G, Calia, R, Spoletini, G, Agnes, S, Grieco, A, Rossi, M, Corradini, S, Vivarelli, M, Benedetti, A, Lupo, L, Rendina, M, Colledan, M, Fagiuoli, S, Cescon, M, Donato, C, Zamboni, F, Mameli, L, De Carlis, L, Belli, L, Rossi, G, Donato, F, Mazzaferro, V, Bhoori, S, Di Benedetto, F, De Maria, N, Santaniello, W, Di Costanzo, G, Gruttadauria, S, Volpes, R, De Simone, P, Carrai, P, Spada, M, Nobile, V, Ettorre, G, Giannelli, V, Tisone, G, Lenci, I, Romagnoli, R, Martini, S, Risaliti, A, Toniutto, P, Tedeschi, U, Carraro, A, Burra, P, and Cillo, U

Subjects
Pediatrics, medicine.medical_specialty, Case mix index, Hepatology, liver transplantation, business.industry, medicine.medical_treatment, Gastroenterology, medicine, Patient survival, Liver transplantation, business
Published
2019

6. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen

Author

Mario Starace, Valerio Giannelli, Nunzia Cuomo, Vanni Borghi, Aldo Bertoli, Anna Licata, Anna Claudia Pellicelli, C. Minichini, M. Andreoni, M. Di Stefano, Giuseppe Cariti, Enzo Boeri, Raffaele Cozzolongo, Roberto Gulminetti, E. Milano, Valeria Cento, Elisabetta Degasperi, Laura Sighinolfi, A. Raddi, Ivana Maida, Barbara Rossetti, Teresa Santantonio, Valeria Micheli, C. Masetti, P. Andreone, Giustino Parruti, F. Di Lorenzo, Ilaria Lenci, Tiziano Allice, Annapaola Callegaro, Elisa Biliotti, M. Lichtner, Teresa Pollicino, Pietro Lampertico, Gloria Taliani, Caterina Pasquazzi, Piero Colombatto, Alessia Giorgini, G. Raimondo, Antonio Craxì, Francesca Ceccherini-Silberstein, Filomena Morisco, Valeria Ghisetti, V.C. Di Maio, Giuliano Rizzardini, Silvia Galli, Stefania Paolucci, A. De Santis, A. Lleo, Vincenzo Sangiovanni, A. Ciancio, Maurizio Zazzi, Elisabetta Teti, Simona Marenco, William Gennari, Stefano Novati, Giovanni Cenderello, Simona Landonio, Manuela Merli, A. Scuteri, Nicola Coppola, C.F. Perno, Giulia Morsica, I. Beretta, Claudio Maria Mastroianni, Simona Francioso, Mario Angelico, Laura Ambra Nicolini, Chiara Dentone, Silvia Barbaliscia, G.B. Gaeta, Marianna Aragri, Ennio Polilli, L. Donnarumma, Vincenza Calvaruso, Bianca Bruzzone, Fausto Baldanti, V. Pace Palitti, Roberto Ganga, Maurizia Rossana Brunetto, C. Paternoster, Sergio Babudieri, M. Puoti, Hamid Hasson, and M. Rendina

Subjects
medicine.medical_specialty, Regimen, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, business, NS5A
Published
2020
Full Text
View/download PDF

7. AISF position paper on HCV in immunocompromised patients

Author

Gabriele Missale, Mauro Viganò, Marco Astegiano, Mauro Salizzoni, C. Chialà, Angelo Pera, Patrizia Racca, Massimo Di Maio, Mario Salomone, M. Puoti, Simone Parisi, Paolo Bironzo, M. Rendina, Carla Pasquina, Clodoveo Ferri, Luisa Pasulo, Rita Tozzi, A. Tucci, Pietro Lampertico, Emanuele Angelucci, Bruno Daniele, Patrizia Burra, Franco Riccardini, Marco Lagget, Fabio Salvatore Macaluso, Davide Giuseppe Ribaldone, Luca Miele, Clara Lisa Peroni, Raffaele Bruno, Anna Linda Zignego, Ambrogio Orlando, Giovanni Battista Gaeta, Giuseppe Montrucchio, Daniela Libertucci, Massimo Marignani, Agostino Colli, Enrico Fusaro, Antonio Craxì, Giorgio Maria Saracco, Barbara Imperatrice, Paolo Caraceni, Luisa Giaccone, Chiara Baratelli, Giuliano Torre, Luigi Biancone, Elisabetta De Gasperi, Mario Rizzetto, Maria Grazia Clemente, Francesco Paolo Russo, Aldo Giacardi, Riccardo Volpes, Edoardo G. Giannini, Daniele Curci, Rossella Della Valle, Salvatore Petta, Pierluigi Toniutto, Alessandro Busca, Pietro Vajro, Giorgio Verme, Chiara Mazzarelli, Paolo Grossi, Maria Chiara Ditto, Lorella Orsucci, Umberto Vitolo, Alberto Mella, Salvatore Madonia, Federica Cavallo, Maria Giuseppina Cabras, Stefano Bonora, Massimiliano Conforti, Vito Di Marco, Mario Pirisi, Giuseppe Cariti, Marta Coscia, Giuseppina Brancaccio, L. Scaglione, Stefano Fagiuoli, Alfredo Marzano, Stefano Cusinato, Roberto Minutolo, Giuseppe Rossi, Enrico Brignardello, Maurizia Rossana Brunetto, Marzano A., Angelucci E., Astegiano M., Baratelli C., Biancone L., Bironzo P., Brancaccio G., Brunetto M.R., Bruno R., Burra P., Cabras M.G., Caraceni P., Chiala C., Clemente M.G., Colli A., Daniele B., De Gasperi E., Di Marco V., Ditto M.C., Fagiuoli S., Ferri C., Gaeta G.B., Grossi P.A., Imperatrice B., Lampertico P., Macaluso F.S., Madonia S., Marignani M., Mazzarelli C., Mella A., Missale G., Parisi S., Pasulo L., Puoti M., Rendina M., Ribaldone D., Rossi G., Toniutto P., Tucci A., Vajro P., Vigano M., Volpes R., Zignego A.L., Giannini E.G., Miele L., Russo F.P., Petta S., Bonora S., Brignardello E., Busca A., Cariti G., Cavallo F., Conforti M., Coscia M., Craxi A., Curci D., Cusinato S., Di Maio M., Valle R.D., Fusaro E., Giacardi A., Giaccone L., Lagget M., Libertucci D., Minutolo R., Montrucchio G., Orlando A., Orsucci L., Pasquina C., Pera A., Peroni C.L., Pirisi M., Racca P., Riccardini F., Rizzetto M., Salizzoni M., Salomone M., Saracco G.M., Scaglione L., Torre G., Tozzi R., Vitolo U., Verme G., Angelucci, E, Astegiano, M, Baratelli, C, Biancone, L, Bironzo, P, Brancaccio, G, Brunetto, M, Bruno, R, Burra, P, Cabras, M, l Caraceni, P, Chialà, C, Clemente, M, Colli, A, Daniele, B, De Gasperi, E, Di Marco, V, Ditto, M, Fagiuoli, S, Ferri, C, Gaeta, G, Grossi, P, Imperatrice, B, Lampertico, P, Macaluso, F, Madonia, S, Marignani, M, Mazzarelli, C, Mella, A, Missale, G, Parisi, S, Pasulo, L, Puoti, M, Rendina, M, Ribaldone, D, Rossi, G, Toniutto, P, Tucci, A, Vajro, P, Viganò, M, Volpes, R, Zignego, A, Giannini, E, Miele, L, Russo, F, Petta, S, Bonora, S, Brignardello, E, Busca, A, Cariti, G, Cavallo, F, Conforti, M, Coscia, M, Craxì, A, Curci, D, Cusinato, S, Di Maio, M, Valle, R, Fusaro, E, Giacardi, A, Giaccone, L, Lagget, M, Libertucci, D, Minutolo, R, Montrucchio, G, Orlando, A, Orsucci, L, Pasquina, C, Pera, A, Peroni, C, Pirisi, M, Racca, P, Riccardini, F, Rizzetto, M, Salizzoni, M, Salomone, M, Saracco, G, Scaglione, L, Torre, G, Tozzi, R, Vitolo, U, Verme, G, Marzano, Alfredo, Angelucci, Emanuele, Astegiano, Marco, Baratelli, Chiara, Biancone, Luigi, Bironzo, Paolo, Brancaccio, Giuseppina, Brunetto, Maurizia Rossana, Bruno, Raffaele, Burra, Patrizia, Cabras, Maria Giuseppina, Caraceni, Paolo, Chialà, Claudia, Clemente, Maria Grazia, Colli, Agostino, Daniele, Bruno, De Gasperi, Elisabetta, Di Marco, Vito, Ditto, Maria Chiara, Fagiuoli, Stefano, Ferri, Clodoveo, Gaeta, Giovanni Battista, Grossi, Paolo Antonio, Imperatrice, Barbara, Lampertico, Pietro, Macaluso, Fabio Salvatore, Madonia, Salvatore, Marignani, Massimo, Mazzarelli, Chiara, Mella, Alberto, Missale, Gabriele, Parisi, Simone, Pasulo, Luisa, Puoti, Massimo, Rendina, Maria, Ribaldone, Davide, Rossi, Giuseppe, Toniutto, Pierluigi, Tucci, Alessandra, Vajro, Pietro, Viganò, Mauro, Volpes, Riccardo, Zignego, Anna Linda, Giannini, Edoardo G., Miele, Luca, Russo, Francesco Paolo, Petta, Salvatore, Bonora, Stefano, Brignardello, Enrico, Busca, Alessandro, Cariti, Giuseppe, Cavallo, Federica, Conforti, Massimiliano, Coscia, Marta, Craxì, Antonio, Curci, Daniele, Cusinato, Stefano, Di Maio, Massimo, Valle, Rossella Della, Fusaro, Enrico, Giacardi, Aldo, Giaccone, Luisa, Lagget, Marco, Libertucci, Daniela, Minutolo, Roberto, Montrucchio, Giuseppe, Orlando, Ambrogio, Orsucci, Lorella, Pasquina, Carla, Pera, Angelo, Peroni, Clara Lisa, Pirisi, Mario, Racca, Patrizia, Riccardini, Franco, Rizzetto, Mario, Salizzoni, Mauro, Salomone, Mario, Saracco, Giorgio Maria, Scaglione, Luca, Torre, Giuliano, Tozzi, Rita, Vitolo, Umberto, Verme, Giorgio, and Ditto, MARIA CHIARA

Subjects
medicine.medical_specialty, Transplant Recipient, Comorbidity, Antiviral Agents, Organ transplantation, 03 medical and health sciences, Immunocompromised Host, 0302 clinical medicine, Internal medicine, Neoplasms, medicine, Immunocompromised patient, Humans, Chronic, Intensive care medicine, Antiviral Agent, Hepatology, business.industry, Gastroenterology, Hepatitis C, Chronic, medicine.disease, Hepatitis C, Organ transplant, HCV, Immunocompromised patients, Transplant Recipients, Immunocompetence, Italy, 030220 oncology & carcinogenesis, HCV, Immunocompromised patients, Organ transplant, Position paper, Neoplasm, 030211 gastroenterology & hepatology, business, Direct acting, Human
Abstract

This report summarizes the clinical features and the indications for treating HCV infection in immunocompromised and transplanted patients in the Direct Acting Antiviral drugs era.

Published
2018

8. OC.01.2 DE NOVO NEOPLASMS AFTER LIVER TRANSPLANTATION: DONOR GENDER AND AGE INFLUENCE

Author

A. Di Leo, Pierluca Piselli, L. Galatioto, Fausto Zamboni, Martina Taborelli, Diego Serraino, G. Tisone, Luca Toti, Umberto Baccarani, C. Becchetti, Salvatore Gruttadauria, Francesco Russo, A. Ruzzarin, Alberto Zanetto, Giuseppe Maria Ettorre, Sarah Shalaby, Francesco Nudo, N. Zeni, Patrizia Boccagni, Marco Senzolo, A.D. Pinna, Giovanni Vennarecci, U. Cillo, G. Fantola, Augusto Lauro, Martina Gambato, S.S. Sciarrone, Giacomo Germani, Alberto Ferrarese, P. Burra, Raffaella Petrara, Andrea Risaliti, Marcos A. Rossi, M. Rendina, and Giacomo Zanus

Subjects
Age and gender, medicine.medical_specialty, Hepatology, business.industry, Internal medicine, medicine.medical_treatment, Gastroenterology, Medicine, Liver transplantation, business
Published
2019
Full Text
View/download PDF

9. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience

Author

Pietro Lampertico, Valeria Cento, Claudio Maria Mastroianni, M. Puoti, Giuliano Rizzardini, Maurizio Zazzi, M. Lichtner, Bianca Bruzzone, Ivana Maida, Elisabetta Degasperi, C.F. Perno, M. Rendina, Giustino Parruti, Vincenza Calvaruso, Gloria Taliani, F. Di Lorenzo, Ilaria Lenci, Anna Claudia Pellicelli, Caterina Pasquazzi, Stefania Paolucci, A. Raddi, Marianna Aragri, Ennio Polilli, Giulia Morsica, Mario Starace, M. Andreoni, M. Di Stefano, C. Minichini, L. Donnarumma, V. Guarneri, Simona Marenco, Simona Landonio, Raffaele Cozzolongo, V. Pace Palitti, N. Cuomo, P. Andreone, Nicola Coppola, Silvia Galli, Mario Angelico, C. Paternoster, Roberto Ganga, Vanni Borghi, Elisabetta Teti, Sergio Babudieri, Silvia Barbaliscia, Anna Licata, Giovanni Cenderello, Antonio Craxì, Filomena Morisco, Maurizia Rossana Brunetto, V.C. Di Maio, Vincenzo Sangiovanni, A. Ciancio, Piero Colombatto, Valeria Micheli, Teresa Pollicino, Laura Ambra Nicolini, Alessia Giorgini, Valeria Ghisetti, S. Novati, Annapaola Callegaro, Aldo Bertoli, E. Milano, Roberto Gulminetti, A. De Santis, F. Ceccherini-Silberstein, Teresa Santantonio, C. Masetti, G. Raimondo, Di Maio, V.C., Aragri, M., Masetti, C., Paolucci, S., Bruzzone, B., Degasperi, E., Barbaliscia, S., Pollicino, T., Minichini, C., Calvaruso, V., Rendina, M., Cento, V., Teti, E., Micheli, V., Ghisetti, V., Polilli, E., Palitti, V. Pace, Landonio, S., Lenci, I., Donnarumma, L., Nicolini, L.A., Bertoli, A., Starace, M., Pasquazzi, C., Callegaro, A.P., Morisco, F., Cenderello, G., Marenco, S., Gulminetti, R., Novati, S., Guarneri, V., Andreone, P., Galli, S., Ciancio, A., Sangiovanni, V., Cuomo, N., Raddi, A., Morsica, G., Borghi, V., Maida, I., Brunetto, M., Colombatto, P., Cozzolongo, R., De Santis, A., Lichtner, M., Babudieri, S., Taliani, G., Santantonio, T., Di Stefano, M., Paternoster, C., Ganga, R., Puoti, M., Rizzardini, G., Pellicelli, A., Milano, E., Mastroianni, C., Licata, A., Di Lorenzo, F., Giorgini, A., Lampertico, P., Parruti, G., Coppola, N., Zazzi, M., Raimondo, G., Andreoni, M., Craxì, A., Angelico, M., Perno, C.F., and Ceccherini-Silberstein, F.

Subjects
Resistance test, medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, DAA failur, Vironet C, NS5A, Regimen, Internal medicine, medicine, retreatment, business
Abstract

Previous article in issueNext article in issue Introduction: There is a limited documentation about the retreatment of patients failing a recommended NS5A-containing regimen in Italy. Materials & methods: Within the VIRONET-C network, 386 NS5A-failing patients infected with different HCV-genotypes (GT) (GT1a/1b/2a-c/3a-b-g-h/4a-d-n-o-v=93/124/19/112/38) were analyzed. Retreatment of 105 failures was investigated. HCV-resistance-test was performed by Sanger-sequencing. Results: Failures following seven different NS5A-containing regimens were studied: 3D/2D (paritaprevir/ombitasvir ± dasabuvir) ± ribavirin (N = 72/4), daclatasvir/ledipasvir/velpatasvir + sofosbuvir ± ribavirin (N = 105/131/20), grazoprevir/elbasvir ± ribavirin (N = 34), glecaprevir/pibrentasvir (N = 20). Notably, 18.1% of NS5A-failing patients did not show any resistance-associated-substitutions (RAS), while 81.9% showed at least one NS5A-RAS, with multiclass-resistance in 35.5%. NS5A-RAS were observed more frequently in glecaprevir/pibrentasvir failures (GT1a 83.3%: Y93H + Q30H/D or +H58D; GT3a: 83.3% Y93H + A30K/G or +L31I) compared to sofosbuvir/velpatasvir (GT1a 16.6%: Y93H + Q30H, p = 0.08; GT3a 20.0%: Y93H/N + A30K/T, p = 0.03). To date, 105 failures have started a retreatment: sofosbuvir/velpatasvir ± ribavirin (N = 30), sofosbuvir/velpatasvir/voxilaprevir ± ribavirin (N = 67), glecaprevir/pibrentasvir (N = 4), grazoprevir/elbasvir ± sofosbuvir + ribavirin (N = 3), 3D + sofosbuvir + ribavirin (N = 1). The majority of patients were cirrhotic (51.9%) and relapsers (87.5%). The prevalence of NS5A-RASs before retreatment was 80.9%, with multiclass-resistance 29.5%. Among patients completing post-retreatment follow-up, a sustained-viral-response at week 12 (SVR12) was observed in 26/33 (78.8%). SVR4 was documented in 49/56 (87.5%). SVR12 was 76.0% with sofosbuvir/velpatasvir ± ribavirin (N = 25). Differently, SVR12 was 100% with glecaprevir/pibrentasvir for 8/12/16 weeks (N = 3), grazoprevir/elbasvir ± sofosbuvir + ribavirin for 12/24 weeks (N = 3) or 3D + sofosbuvir + ribavirin for 24 weeks (N = 1), despite the presence of NS5A-RASs. Until now, 67 patients started sofosbuvir/velpatasvir/voxilaprevir ± ribavirin recommended-retreatment for 12 weeks. 54/67 (80.6%) showed at least one baseline NS5A-RAS, 23/67 (34.3%) multiple-NS5A-RASs, and 22/67 (32.8%) multiclass-resistance. Of 25 patients with available outcome, 96.0% had SVR4. Only 1 GT1b infected patient was non-responder, without RASs before retreatment. Conclusions: In this real-life setting, NS5A-RASs were frequently detected at failure, and multiclass-resistance was around 30%. Overall, SVR after resistance-test-guided retreatment was >95%, with the exception of the sofosbuvir/velpatasvir retreatment. Our results show how HCV resistance-test at failure may be useful to optimize retreatment strategies.

Published
2019
Full Text
View/download PDF

10. Long term renal safety of HCV direct acting antivirals in HCV positive kidney transplant recipients

Author

Loreto Gesualdo, A. Di Leo, A. Marra, N.M. Castellaneta, S. Mocka, Antonio Schena, Andrea Iannone, Ernesto Paoletti, M. Rendina, E. Bussalino, N. Labarile, A. Castellaneta, and Michele Barone

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Gastroenterology, Medicine, business, DIRECT ACTING ANTIVIRALS, Kidney transplant, Term (time), HCV Positive
Published
2020
Full Text
View/download PDF

11. Comparison of resistance profiles among DAA-naive and DAA-experienced patients infected with HCV non-1 genotype in Italy

Author

Simona Francioso, A. Ciaccio, Teresa Pollicino, Bianca Bruzzone, G. Fiorentino, V. Boccaccio, Coppola Nicola, M. Puoti, Ivana Maida, Valeria Cento, Lucio Boglione, Francesca Ceccherini Silberstein, Valeria Micheli, Silvia Barbaliscia, Sergio Babudieri, Guido Gubertini, Giustino Parruti, Antonio Craxì, Vincenzo Vullo, Ennio Polilli, M. Andreoni, Filomena Morisco, Vincenzo Sangiovanni, Vincenza Calvaruso, Renato Maserati, Velia Chiara Di Maio, Maurizio Zazzi, Marianna Aragri, A. Ciancio, Barbara Rossetti, Anna Claudia Pellicelli, Elisabetta Teti, C.F. Perno, Caterina Pasquazzi, L. Sarmati, R. D’Ambrosio, Mario Angelico, Fosca Niero, Stefano Bonora, M. Rendina, Gloria Taliani, Luca Foroghi, Laura Ambra Nicolini, Aldo Bertoli, A. Lleo, G. Raimondo, T. Ruggiero, Simona Marenco, Valeria Pace Palitti, G.B. Gaeta, Stefania Paolucci, and Ilaria Lenci

Subjects
Hepatology, Resistance (ecology), business.industry, Genotype, Medicine, business, Virology
Published
2018
Full Text
View/download PDF

12. Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis

Author

M. Mangano, Raffaella Viganò, Ilaria Lenci, Fabio Conti, M. Rendina, L. Pasulo, Laura Loiacono, Federica Malinverno, P. Burra, Paolo Pianta, Francesco Paolo Russo, Rosa Maria Iemmolo, Pietro Andreone, Pierluigi Toniutto, Antonietta Romano, Stefano Fagiuoli, Luca S. Belli, Francesco Giuseppe Foschi, Maria Francesca Donato, Paola Carrai, Mariarosa Tamè, Antonio Picciotto, S. Monico, A. M. Degli Antoni, Sonia Berardi, M.C. Morelli, Ranka Vukotic, Giuseppe Mazzella, Manuela Merli, M. Colpani, Vukotic, R, Conti, F, Fagiuoli, S, Morelli, M, Pasulo, L, Colpani, M, Foschi, F, Berardi, S, Pianta, P, Mangano, M, Donato, M, Malinverno, F, Monico, S, Tame, M, Mazzella, G, Belli, L, Vigano, R, Carrai, P, Burra, P, Russo, F, Lenci, I, Toniutto, P, Merli, M, Loiacono, L, Iemmolo, R, Degli Antoni, A, Romano, A, Picciotto, A, Rendina, M, Andreone, P, Morelli, M C, Foschi, F G, Donato, M F, Tamè, M, Belli, L S, Viganò, R, Russo, F P, and Degli Antoni, A M

Subjects
Liver Cirrhosis, Male, Simeprevir, Time Factors, Sofosbuvir, Hepacivirus, Kaplan-Meier Estimate, medicine.disease_cause, Severity of Illness Index, Gastroenterology, Hepatitis, chemistry.chemical_compound, 0302 clinical medicine, Liver Function Tests, fibrosing cholestatic hepatiti, Recurrence, antiviral therapy, Viral, fibrosing cholestatic hepatitis, liver transplant, long-term outcome, severe hepatitis C virus recurrence, Aged, Antiviral Agents, Drug Therapy, Combination, Female, Genotype, Hepatitis C, Humans, Liver Transplantation, Middle Aged, RNA, Viral, Treatment Outcome, Viral Load, Hepatology, Infectious Diseases, Virology, 030220 oncology & carcinogenesis, Combination, 030211 gastroenterology & hepatology, medicine.drug, medicine.medical_specialty, Daclatasvir, Hepatitis C virus, 03 medical and health sciences, Drug Therapy, Internal medicine, medicine, business.industry, Ribavirin, medicine.disease, chemistry, RNA, Liver function, business
Abstract

Long-term functional outcomes of sofosbuvir-based antiviral treatment were evaluated in a cohort study involving 16 Italian centres within the international compassionate use programme for post-transplant hepatitis C virus (HCV) recurrence. Seventy-three patients with cirrhosis (n=52) or fibrosing cholestatic hepatitis (FCH, n=21) received 24-week sofosbuvir with ribavirin±pegylated interferon or interferon-free sofosbuvir-based regimen with daclatasvir/simeprevir+ribavirin. The patients were observed for a median time of 103 (82-112) weeks. Twelve of 73 (16.4%) died (10 non-FCH, 2 FCH) and two underwent re-LT. Sustained virological response was achieved in 46 of 66 (69.7%): 31 of 47 (66%) non-FCH and 15 of 19 (79%) FCH patients. All relapsers were successfully retreated. Comparing the data of baseline with last follow-up, MELD and Child-Turcotte-Pugh scores improved both in non-FCH (15.3±6.5 vs 10.5±3.8, P

Published
2017

13. SVR is the strongest predictor of occurrence and recurrence of hepatocellular carcinoma in HCV cirrhotic patients after treatment with direct acting antivirals: A prospective multicenter Italian study

Author

Andrea Aglitti, Fabio Conti, M. Rendina, A. Di Leo, A. Ciancio, Elisabetta Degasperi, L. Marzi, P. Andreone, Massimo Zuin, S. Bruno, Pietro Lampertico, Simona Bollani, Alessio Aghemo, Maurizia Rossana Brunetto, Vincenza Calvaruso, Ana Lleo, Patrick Maisonneuve, Erica Villa, Alessia Giorgini, Marcello Persico, V. Boccaccio, Barbara Coco, Giulia Troshina, and V. Di Marco

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Hepatocellular carcinoma, Internal medicine, Gastroenterology, medicine, business, medicine.disease, DIRECT ACTING ANTIVIRALS, After treatment
Published
2018
Full Text
View/download PDF

15. SVR is the strongest predictor of occurrence and recurrence of hepatocellular carcinoma in HCV cirrhotic patients after treatment with DAAs: a prospective multi-centric Italian study

Author

Vincenza Calvaruso, V. Boccaccio, Pietro Lampertico, Patrick Maisonneuve, Alessio Aghemo, Alessia Giorgini, Giulia Troshina, Elisabetta Degasperi, V. Di Marco, Fabio Conti, Ana Lleo, Maurizia Rossana Brunetto, Massimo Zuin, Simona Bollani, P. Andreone, A. Di Leo, L. Marzi, Barbara Coco, Erica Villa, Marcello Persico, S. Bruno, M. Rendina, Andrea Aglitti, and A. Ciancio

Subjects
medicine.medical_specialty, Hepatology, business.industry, medicine.disease, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Hepatocellular carcinoma, medicine, 030211 gastroenterology & hepatology, business, After treatment
Published
2018
Full Text
View/download PDF

16. P.09.26 GENETIC AND METABOLIC RISK FACTOR FOR 'DE NOVO' NON ALCOHOLIC FATTY LIVER DISEASE IN LIVER TRANSPLANT PATIENTS

Author

Michele Barone, A. Castellaneta, N. Labarile, M. Gentile, Giuseppe Losurdo, Claudia Sorrentino, A. Di Leo, L. Lupo, M. Rendina, and A. Marra

Subjects
medicine.medical_specialty, Hepatology, business.industry, Metabolic risk, Fatty liver, Gastroenterology, Non alcoholic, Disease, medicine.disease, Internal medicine, medicine, Transplant patient, business
Published
2018
Full Text
View/download PDF

17. Slow achievement of HCV-RNA undetectability in cirrhotic patients treated with sofosbuvir+ribavirin: possible clinical implications in the liver transplant list management

Author

V.C. Di Maio, Francesca Ceccherini-Silberstein, Ilaria Lenci, Luciano Milanesi, Maria Chiara Colombo, M. Manuelli, Maria Francesca Donato, A. Castellaneta, Roberta Alfieri, M. Rendina, Martina Milana, Maria Laura Ponti, R. Canu, A. Di Leo, C.F. Perno, R. Ganga, Federica Malinverno, S. Monico, Mario Angelico, Valeria Cento, Daniele Sforza, Marianna Aragri, A. Abedrabbo, and Giuseppe Tisone

Subjects
chemistry.chemical_compound, medicine.medical_specialty, Hepatology, chemistry, Sofosbuvir, business.industry, Ribavirin, Internal medicine, Gastroenterology, medicine, business, medicine.drug
Abstract

Sofosbuvir (SOF) treatment ± ribavirin (RBV) prior to LT has the potential to change the HCV recurrence after Liver Transplantation (LT). This approach has been reported to avoid graft reinfection in compensated patients with hepatocellular carcinoma (HCC), but only among those who reached and maintained undetectable HCV-RNA (TND) before LT. Since the time to obtain this result in decompensated cirrhotics is unknown, we sought to investigate the early HCV-RNA decay in this setting. Sixteen decompensated patients (M/F 12/4, median age 55.3, CPT score>=B7), infected by HCV genotype 1a, 1b, 3 and 4 (2-8- 4-2), 4 of whom with HCC, were treated with SOF 400mg/day and RBV (200-1000 mg/day), except 2 who received SOF alone, for a median(IQR) of 12(11-16) weeks awaiting LT. HCV-RNA levels were measured weekly and safety and clinical parameters were analyzed. No serious adverse events were reported. The median(IQR) RBV dose was 600(400-800). Despite 11/16 patients had low baseline viremia (

Published
2015
Full Text
View/download PDF

18. Design and test of a multi-input multi-output adaptive active flutter suppression system based on neural network for a wing model

Author

G. Mazzoni and M. Rendina

Subjects
Engineering, Wing, Artificial neural network, business.industry, General Engineering, Control engineering, Flight control surfaces, Accelerometer, Deflection (engineering), Control theory, Control system, Trailing edge, Flutter, business
Abstract

This paper describes the application of a recurrent dynamic neural network to the problem of adaptive active flutter suppression. A significant feature of the neural controller is its application to an unstable and non-minimum phase system. The development of the system and its experimental verification are carried out on a wing model with two control surfaces, one on the leading and one at the trailing edge, and two accelerometers. The controller combines a first network for the identification of the variables to be controlled, i.e. the two wing tip accelerations at the leading and trailing edge, with a second network, that commands the deflection required to the control surfaces. It is used for the control task using the output generated by the first network. Adaptivity is obtained by maintaining an on-line training on both of the neural networks. Extensive preliminary numerical simulations have permitted the authors to define the values of the design parameters aimed at the achievement of an optimal compromise between computational requirements and system performances. The results of the application to the real wing model have shown the effectiveness of such a controller in adapting to different operational conditions, extending flutter free envelope of the wing model up to a speed 30% higher than the uncontrolled flutter onset.

Published
1999
Full Text
View/download PDF

19. Analysis of Predictive Factors of Non Response to Therapy in Autoimmune Hepatitis-Primary Biliary Cirrhosis Overlap Syndromes a Retrospective Singlecenter Experience

Author

M. Rendina, A. Di Leo, S. Carparelli, Antonio Facciorusso, R. Licinio, and N.M. Castellaneta

Subjects
medicine.medical_specialty, Primary biliary cirrhosis, Hepatology, Response to therapy, business.industry, Internal medicine, medicine, Autoimmune hepatitis, medicine.disease, business, Gastroenterology
Published
2016
Full Text
View/download PDF

20. A multicentre prospective study response to treatment in genotype 3 and 1b infected patients with sickest liver cirrhosis: SVR 4 is not a reliable measure

Author

M. Rendina, Alessia Giorgini, A. Ciancio, Maurizia Rossana Brunetto, Simona Bollani, Massimo Zuin, S. Bruno, Andrea Aglitti, Fabio Conti, P. Andreone, Erica Villa, Marcello Persico, Ana Lleo, V. Di Marco, Y. Toshina, Alessio Aghemo, Vincenza Calvaruso, A. Di Leo, S. De Nicola, Barbara Coco, and L. Marzi

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, Gastroenterology, Measure (physics), medicine.disease, Response to treatment, Internal medicine, Genotype, medicine, business, Prospective cohort study
Published
2016
Full Text
View/download PDF

21. OC.04.6 EARLY VIROLOGICAL RESPONSE IS THE MAIN PREDICTOR OF VIRAL ERADICATION IN HCV HAEMODIALYSIS PATIENTS TREATED WITH PEGYLATED INTERFERON PLUS RIBAVIRIN

Author

Gioacchino Leandro, C. Chialà, N.M. Castellaneta, A. Di Leo, A. Castellaneta, A. Tucci, Loreto Gesualdo, and M. Rendina

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, Ribavirin, Gastroenterology, medicine.disease, Medical care, Virus, Virological response, chemistry.chemical_compound, Liver disease, chemistry, Pegylated interferon, Internal medicine, medicine, Coinfection, business, medicine.drug
Abstract

s / Digestive and Liver Disease 46 (2014) e1–e17 e13 34/295 immigrates (11.5%; p=0.036). Italian patients with HDV were older (median age 51.1 vs 36.3; p

Published
2014
Full Text
View/download PDF

23. LP51 : Treatment of severe HCV recurrence after liver transplantation with sofosbuvir based regimen: Results of the aisf-sofolt Italian compassionate use program

Author

Francesco Giuseppe Foschi, Maria Francesca Donato, Raffaella Viganò, P. Burra, Paolo Pianta, Ilaria Lenci, M. Colpani, L. Pasulo, Paola Carrai, Manuela Merli, A. Degli Antoni, Fabio Conti, Pierluigi Toniutto, Federica Malinverno, Antonietta Romano, Francesco Russo, Mariarosa Tamè, Sonia Berardi, Ranka Vukotic, Giuseppe Mazzella, P. Andreone, Laura Loiacono, Stefano Fagiuoli, Rosa Maria Iemmolo, M.C. Morelli, Antonio Picciotto, Luca S. Belli, and M. Rendina

Subjects
Regimen, medicine.medical_specialty, Hepatology, Sofosbuvir, business.industry, medicine.medical_treatment, medicine, Hcv recurrence, Compassionate Use, Liver transplantation, business, medicine.drug, Surgery
Published
2015
Full Text
View/download PDF

24. P0903 : Slow HCV kinetics following sofosbuvir + ribavirin administration in real-life setting of liver transplant recipients with severe recurrent hepatitis C

Author

C. Chialà, R. Canu, Maria Chiara Colombo, Giuseppe Tisone, Francesca Ceccherini-Silberstein, Fausto Zamboni, V.C. Di Maio, Antonio Picciotto, Luciano Milanesi, M. Manuelli, Giorgio Rossi, Ilaria Lenci, A. Di Leo, L. Mameli, M.C. Sorbo, M. Rendina, Daniele Sforza, Roberta Alfieri, Simona Marenco, A. Abedrabbo, Maria Francesca Donato, M.L. Ponti, Martina Milana, R. Ganga, Federica Malinverno, Valeria Cento, C.F. Perno, Marianna Aragri, S. Monico, and Mario Angelico

Subjects
medicine.medical_specialty, Hepatology, Sofosbuvir, business.industry, Ribavirin, Gastroenterology, chemistry.chemical_compound, chemistry, Internal medicine, medicine, In real life, Recurrent hepatitis, business, medicine.drug
Published
2015
Full Text
View/download PDF

25. Italian survey on HBV and liver transplantation in a cohort of 2260 patients

Author

Mariarosa Tamè, F. Caneschi, R. Fasulo, Manuela Merli, Mauro Salizzoni, I. Bortoluzzi, L. Sangiovanni, Ruggiero Francavilla, Paolo Forte, Guido Piai, P. Conoscitore, C. Cusumano, Maria Grazia Lucà, Laura Staiano, G. Parrilli, Riccardo Volpes, P. Andreone, Patrizia Boccagni, Giuseppe Tisone, Carmine Coppola, Nicola Caporaso, Patrizia Burra, M. Mazzola, Angelo V. Marzano, Rosa Maria Iemmolo, S. Bongiovanni, I. Lenisa, D. Cocchis, L. De Carlis, G.B. Gaeta, Giovanni Vennarecci, S. Mirabella, A. Lotti Suffredini, Stefano Fagiuoli, Ranka Vukotic, M. Scarpellini, Iacopo Mangoni, G. Stornaiuolo, M.R. Piras, M. Rendina, V. Giannelli, P. Russo, L. Mameli, Alessandro Anselmo, Lucio Caccamo, Fausto Zamboni, and Pierluigi Toniutto

Subjects
medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Internal medicine, Cohort, Gastroenterology, Medicine, Liver transplantation, business
Published
2014
Full Text
View/download PDF

26. OC-24 Interaction between cyclosporine and recipient IL-28B rs12979860 C>T genetic polymorphisms in the achievement of sustained viral response for recurrent hepatitis C

Author

Cristina Rigamonti, Annarosa Cussigh, Lino Belli, Stefano Fagiuoli, Sara Cmet, S. Ginanni Corradini, Carlo Fabris, Pierluigi Toniutto, F.R. Ponziani, M. Rendina, Ezio Fornasiere, P. Burra, Francesco Donato, Edmondo Falleti, Davide Bitetto, Luisa Pasulo, T. De Feo, Raffaella Viganò, Alessandro Gasbarrini, and E. De Martin

Subjects
Hepatology, business.industry, Immunology, Gastroenterology, Medicine, Sustained viral response, Recurrent hepatitis, business
Published
2012
Full Text
View/download PDF

27. P.1.129: LIVER STIFFNESS MEASUREMENTS IS ABLE TO PREDICT GRAFT FAILURE IN PATIENTS WITH ESTABLISHED HCV RECURRENCE AFTER LIVER TRANSPLANTATION

Author

N.M. Castellaneta, M. Rendina, S.F. Rizzi, L. Lupo, A. Francavilla, A. Di Leo, M. Zappimbulso, R. Bringiotti, and S. Barbalinardo

Subjects
medicine.medical_specialty, Graft failure, Hepatology, business.industry, medicine.medical_treatment, Gastroenterology, Hcv recurrence, Liver transplantation, Liver stiffness, Internal medicine, medicine, In patient, business
Published
2011
Full Text
View/download PDF

28. 523 PROTRACTED ANTIVIRAL TREATMENT BEYOND CONVENTIONAL TIME LIMITS IMPROVES SURVIVAL IN NON-RESPONDERS TO INTERFERON+RIBAVIRIN ADMINISTERED FOR HCV RECURRENCE AFTER LIVER TRANSPLANTATION

Author

Luisa Pasulo, Ezio Fornasiere, P. Burra, L. Miglioresi, Maurizio Pompili, Raffaella Viganò, D. Di Paolo, Valerio Giannelli, Maria Francesca Donato, F.R. Ponziani, M. Rendina, Valentina Rosa Bertuzzo, M. Marino, Matteo Cescon, and Stefano Fagiuoli

Subjects
medicine.medical_specialty, Hepatology, business.industry, Ribavirin, medicine.medical_treatment, Hcv recurrence, Liver transplantation, Gastroenterology, chemistry.chemical_compound, Non responders, chemistry, Interferon, Internal medicine, Medicine, Antiviral treatment, business, medicine.drug
Published
2011
Full Text
View/download PDF

29. P.1.3: ACUTE AND CHRONIC REJECTION DURING INTERFERON THERAPY IN HCV RECURRENT LIVER TRANSPLANT PATIENTS: RESULTS FROM THE AISF-RECOLT-C GROUP

Author

Valerio Giannelli, N.M. Castellaneta, Pierluigi Toniutto, M.C. Morelli, Stefano Fagiuoli, Luisa Pasulo, P. Burra, D. Di Paolo, Rosa Maria Iemmolo, L. Miglioresi, A. Di Leo, F.R. Ponziani, M. Rendina, Maria Francesca Donato, and Raffaella Viganò

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, Interferon therapy, Transplant patient, business
Published
2011
Full Text
View/download PDF

30. T-44 Impact of antiviral therapy on fibrosis progression due to HCV recurrence after liver transplantation: Results from the AISF RECOLT-C study group

Author

Valerio Giannelli, M.C. Morelli, Marco Senzolo, P. Burra, E. De Martin, Raffaella Viganò, M. Marino, D. Di Paolo, E. Fornasiero, Maria Francesca Donato, F.R. Ponziani, Stefano Fagiuoli, M. Rendina, and L. Miglioresi

Subjects
medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Gastroenterology, Antiviral therapy, Hcv recurrence, Liver transplantation, medicine.disease, Fibrosis, Internal medicine, medicine, business
Published
2011
Full Text
View/download PDF

31. P885 RECIPIENT AND DONOR GENDER MATCH PREDICTS THE OUTCOME OF ANTIVIRAL THERAPY FOR RECURRENT HEPATITIS C

Author

Silvia Pecere, F.R. Ponziani, Davide Bitetto, Stefano Fagiuoli, M. Rendina, Francesco Donato, Pierluigi Toniutto, D. Di Paolo, Luisa Pasulo, L. Miglioresi, Manuela Merli, Rosa Maria Iemmolo, Lino Belli, Alessandro Gasbarrini, P. Burra, and M.C. Morelli

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Antiviral therapy, Medicine, Recurrent hepatitis, business, Outcome (game theory)
Published
2014
Full Text
View/download PDF

32. Immuno-modulating effects of Silibinin in liver transplant patients with HCV recurrence

Author

M. D’Amato, A. Tucci, G. Giacovelli, L. Rovati, N.M. Castellaneta, A. Di Leo, Antonio Massaro, M. Rendina, Nadia Brambilla, C. Chialà, F. D’Errico, and A. Castellaneta

Subjects
chemistry.chemical_compound, medicine.medical_specialty, Hepatology, chemistry, business.industry, Internal medicine, Gastroenterology, Medicine, Silibinin, Hcv recurrence, Transplant patient, business
Published
2014
Full Text
View/download PDF

33. 176 PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT STUDY EVALUATING EFFICACY AND SAFETY OF INTRAVENOUS SILIBININ IN PATIENTS WITH HCV RECURRENCE ON THE GRAFT AFTER LIVER TRANSPLANTATION

Author

Massimo D'Amato, Lucio C. Rovati, S.F. Rizzi, M. Rendina, A. Di Leo, Nadia Brambilla, M. Zappimbulso, R. Bringiotti, Giampaolo Giacovelli, N.M. Castellaneta, and A. Castellaneta

Subjects
medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Hcv recurrence, Silibinin, Liver transplantation, Placebo, Surgery, Double blind, chemistry.chemical_compound, chemistry, Internal medicine, medicine, In patient, business
Published
2013
Full Text
View/download PDF

34. P.18.2 LONG-TERM MAINTENANCE OF SVR IN DIFFICULT-TO-TREAT HCV GENOTYPES IN LIVER TRANSPLANT RECIPIENTS WITH HCV RECURRENCE

Author

Stefano Fagiuoli, F.R. Ponziani, Rosa Maria Iemmolo, Raffaella Viganò, Maria Francesca Donato, Alessandro Gasbarrini, P. Burra, D. Di Paolo, L. Miglioresi, F. D'Aversa, Manuela Merli, M. Rendina, Luisa Pasulo, Maurizio Pompili, M.C. Morelli, Pierluigi Toniutto, Raffaella Zaccaria, and A. Milani

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, HCV genotypes, Hcv recurrence, Long term maintenance, business
Published
2013
Full Text
View/download PDF

35. T-48 Efficacy and safety of intravenous silibinin in patients with HCV recurrence on the graft after liver transplantation (LT): a prospective, randomized, double-blind, placebo-controlled pilot study

Author

M. D’Amato, A. Castellaneta, A. Di Leo, G. Giacovelli, L. Rovati, Nadia Brambilla, M. Zappimbulso, N.M. Castellaneta, R. Bringiotti, S.F. Rizzi, and M. Rendina

Subjects
medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Gastroenterology, Silibinin, Hcv recurrence, Liver transplantation, Placebo, Surgery, Double blind, chemistry.chemical_compound, chemistry, Internal medicine, medicine, In patient, business
Published
2013
Full Text
View/download PDF

36. The Fifth Element in Drug Design: Boron in Medicinal Chemistry

Author

Michael Kassiou, Christopher J.D. Austin, Louis M. Rendina, and Jan Kahlert

Subjects
inorganic chemicals, Drug, Green chemistry, Research groups, business.industry, media_common.quotation_subject, Supramolecular chemistry, chemistry.chemical_element, New materials, Nanotechnology, Boranes, General Chemistry, Medicinal chemistry, chemistry, Boron, business, Pharmaceutical industry, media_common
Abstract

The unique chemistry of boron allows for the utilisation of novel building-blocks which are not traditionally found in medicinal chemistry. The pharmaceutical industry has begun to exploit boronic acid derivatives as new drugs and several research groups are also exploring 1,2-azaborines and icosahedral boranes known as carboranes as boron-based structural motifs, with great promise for innovative drug design. Recent advances in the medicinal chemistry of these three important boron moieties are highlighted and illustrated with selected examples.

Published
2013
Full Text
View/download PDF

37. Can the Un-Sustainable Match Be Identified in Liver Transplant Population? Evidencies from the Italian Donor-2-Recipient D-Meld Study

Author

L. De Carlis, Alessandro Vitale, A. Cucchetti, Vincenzo Mazzaferro, Marcos A. Rossi, M. Rendina, M. Gelli, Enrico Regalia, Fausto Zamboni, L. Lupo, Alessandro Perrella, Salvatore Agnes, Iacopo Mangoni, Fulvio Calise, Roberto Montalti, Daniele Nicolini, Francesco Frongillo, M. C. Lirosi, Quirino Lai, Renato Romagnoli, C. de Waure, Tommaso Maria Manzia, Domenico Pinelli, E. Tondolo, G. Tisone, Nicola Nicolotti, Mauro Salizzoni, A.D. Pinna, Umberto Baccarani, B. Antonelli, Fabrizio Bresadola, Salvatore Gruttadauria, E. Scuderi, Umberto Valente, Giuseppe Maria Ettorre, U. Cillo, Michele Colledan, O. Cuomo, Giovanni Vennarecci, Lucio Caccamo, Alessandro Gasbarrini, P. Burra, Andrea Risaliti, Gemma Rossi, B. Gridelli, A.W. Avolio, and G.E. Gerunda

Subjects
Transplantation, education.field_of_study, business.industry, Population, Medicine, business, education, Demography
Published
2012
Full Text
View/download PDF

38. 85 INTERACTION BETWEEN CYCLOSPORINE AND RECIPIENT IL-28B RS12979860 C>T GENETIC POLYMORPHISMS IN THE ACHIEVEMENT OF SUSTAINED VIRAL RESPONSE FOR RECURRENT HEPATITIS C

Author

Stefano Fagiuoli, Edmondo Falleti, Annarosa Cussigh, Ezio Fornasiere, P. Burra, Pierluigi Toniutto, Sara Cmet, Carlo Fabris, Luisa Pasulo, Davide Bitetto, Lino Belli, M. Rendina, T. De Feo, Cristina Rigamonti, F.R. Ponziani, Francesco Donato, Raffaella Viganò, Alessandro Gasbarrini, S. Ginanni-Corradini, and E. De Martin

Subjects
Hepatology, business.industry, Immunology, Sustained viral response, Medicine, Recurrent hepatitis, business
Published
2012
Full Text
View/download PDF

39. P.03.6 IS THE PRIMARY IMMUNOSUPPRESSIVE DRUG (CYCLOSPORIN A OR TACROLIMUS) PLAYING A ROLE ON THE RESPONSE TO ANTIVIRAL TREATMENT FOR POST-TRANSPLANT HCV RECURRENCE?

Author

V. Vero, Valerio Giannelli, Marco Senzolo, Pierluigi Toniutto, Matteo Cescon, Luisa Pasulo, Stefano Fagiuoli, D. Di Paolo, M. Rendina, Raffaella Viganò, Alessandro Gasbarrini, L. Miglioresi, F.R. Ponziani, and E. De Martin

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Gastroenterology, Hcv recurrence, Virology, Tacrolimus, Post transplant, Immunosuppressive drug, Cyclosporin a, Internal medicine, medicine, Antiviral treatment, business
Published
2012
Full Text
View/download PDF

40. P.04.9 THE PRESENCE OF DIABETES REDUCES SVR AFTER ANTIVIRAL THERAPY FOR POST-TRANSPLANT HCV RECURRENCE

Author

L. Miglioresi, Stefano Fagiuoli, M. Marino, Maria Francesca Donato, D. Di Paolo, Valerio Giannelli, M. Rendina, V. Vero, F.R. Ponziani, Matteo Cescon, Luisa Pasulo, Marco Senzolo, Pierluigi Toniutto, E. De Martin, Raffaella Viganò, and Alessandro Gasbarrini

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Diabetes mellitus, Internal medicine, Gastroenterology, medicine, Antiviral therapy, Hcv recurrence, business, medicine.disease, Post transplant
Published
2012
Full Text
View/download PDF

41. P.04.4 SVR TO ANTIVIRAL TREATMENT FOR POST-OLT RECURRENT HCV HEPATITIS CAN BE IMPROVED BY THE USE OF GROWTH FACTORS

Author

Valerio Giannelli, Matteo Cescon, Raffaella Viganò, Alessandro Gasbarrini, M. Rendina, M. Marino, Pierluigi Toniutto, L. Miglioresi, Maria Francesca Donato, D. Di Paolo, Stefano Fagiuoli, E. De Martin, Luisa Pasulo, V. Vero, Marco Senzolo, and F.R. Ponziani

Subjects
Taurine, medicine.medical_specialty, Hepatology, business.industry, Insulin, medicine.medical_treatment, Gastroenterology, Normal limit, G protein-coupled bile acid receptor, chemistry.chemical_compound, chemistry, Internal medicine, Hcv hepatitis, medicine, Medical history, Antiviral treatment, business, Abdominal surgery
Abstract

Background and aim: Although the lack of extensive data in humans, bile acids (BAs) and particularly CDCA a potent FXR and TGR5 ligand, are signaling molecules in glucose, lipid and energy metabolism. Aim of our study was to evaluate serum BA profile including Glycine (G), Taurine (T) and Unconjugated (U)-Bas in blood donors (BD) and to identify correlations between individual BA concentration in normal and insulin-resistant (IR) subjects. Material and methods:We prospectively enrolled 160 blood donors from our Transfusion Center, from January to June 2011. Exclusion criteria were: alteration in blood tests, history of liver or GI disease, previous abdominal surgery and treatment with metabolic and GI medications. All patients underwent biochemistry tests (fasting glucose and insulin, total cholesterol, HDL, LDL, triglycerides (TG), ALT, GammaGT, ALP) and serum BA profile measurement (HPLC-ESI-MS/MS). All patients underwent an abdominal ultrasound within a week from enrollment. Medical history, laboratory parameters and ultrasonographic findings of all subjects were reviewed from our physicians and subjects were classified as Healthy (H, n=120), IR (n=28) and gallstone subjects (GS, n=12, excluded from analysis). Results: 148 subjects (84 male/64 female; mean age 41.7±12.6) met the inclusion criteria. BMI was 25.1±3.7; total cholesterol 194.6±35.6; HDL 60.5±15.2; TG 91.8±48.7; ALT, GammaGt, ALP and other mean biochemical index were within normal limits. In IR subjects, total serum BAs (5.02±2.39 vs 3.56±2.55 μmol/l; P= 0.0017), serum unconjugated BAs (1.95±1.25 vs 1.40±1.17 μmol/l; P= 0.025) and CDCA (2.28±1.39 vs 1.63±1.43; P=0.03) were significantly higher than in healthy subjects. On multivariate analysis, BMI (r=0.35; P

Published
2012
Full Text
View/download PDF

42. OC-28 Behind D-MELD: the role of primary indication (HCV or HBV) as significant covariate in the outcome prediction after liver transplants

Author

Tommaso Maria Manzia, F. Montalti, Nicola Nicolotti, Enrico Regalia, Fulvio Calise, Domenico Pinelli, Mauro Salizzoni, M. C. Lirosi, A.D. Pinna, C. de Waure, G.E. Gerunda, P. Burra, Alessandro Gasbarrini, Alessandro Perrella, B. Antonelli, O. Cuomo, Iacopo Mangoni, Quirino Lai, Andrea Risaliti, Michele Colledan, Gemma Rossi, Renato Romagnoli, G. Tisone, Giovanni Vennarecci, E. Tondolo, Umberto Valente, A. Cucchetti, Marcos A. Rossi, M. Rendina, Lucio Caccamo, Fausto Zamboni, L. Lupo, G.M. Ettore, L. De Carlis, U. Cillo, Salvatore Agnes, Stefano Fagiuoli, Mario Angelico, Pierluigi Toniutto, Umberto Baccarani, A.W. Avolio, B. Gridelli, Alessandro Vitale, Salvatore Gruttadauria, E. Scuderi, M. Gelli, Daniele Nicolini, and Vincenzo Mazzaferro

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, medicine.medical_treatment, Covariate, Gastroenterology, medicine, Liver transplants, Liver transplantation, Outcome prediction, business
Published
2012
Full Text
View/download PDF

43. P.1.5: POOR ADHERENCE TO PEGYLATED INTERFERON AND RIBAVIRIN IS A MAJOR CONCERN IN THE TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: EVIDENCE FROM THE AISF RECOLT-C STUDY GROUP

Author

M. Rendina, Maria Francesca Donato, D. Di Paolo, Stefano Fagiuoli, E. De Martin, G. Tisone, L. Miglioresi, Pierluigi Toniutto, M.C. Morelli, Raffaella Viganò, Rosa Maria Iemmolo, Mario Angelico, F.R. Ponziani, and Manuela Merli

Subjects
medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Ribavirin, Gastroenterology, Liver transplantation, Virology, Poor adherence, chemistry.chemical_compound, chemistry, Pegylated interferon, Internal medicine, Medicine, Recurrent hepatitis, business, medicine.drug
Published
2011
Full Text
View/download PDF

44. P.1.2: THE PERSISTENCE OF HCV REPLICATION IS ASSOCIATED WITH AN INCREASED MORTALITY RATE IN HCV RECURRENT TRANSPLANT PATIENTS: RESULTS FROM THE AISF-RECOLT-C GROUP

Author

F.R. Ponziani, P. Burra, N.M. Castellaneta, L. Miglioresi, Valerio Giannelli, Pierluigi Toniutto, Luisa Pasulo, M.F. Doanto, Stefano Fagiuoli, D. Di Paolo, A. Di Leo, M.C. Morelli, M. Rendina, Raffaella Viganò, and Rosa Maria Iemmolo

Subjects
Sorafenib, Univariate analysis, medicine.medical_specialty, Hepatology, business.industry, Mortality rate, Gastroenterology, medicine.disease, Rash, Portal vein thrombosis, Internal medicine, Hepatocellular carcinoma, Ascites, medicine, medicine.symptom, Varices, business, medicine.drug
Abstract

Background and aim: Sorafenib is a multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma (HCC). However, the predictive factors of outcome among treated patients have not been fully investigated. Aim of this study was to identify factors predictive for tumor control among patients with advanced HCC treated with sorafenib. Material and methods: All consecutive HCC patients treated with sorafenib at our Unit from October 2008 to October 2010 were evaluated. All patients received 800 mg/day of sorafenib until progression or unacceptable toxicities. Overall survival (OS) and time to progression (TTP) were estimated by using Kaplan-Meier curves. TTP was considered as a marker of tumor control. Univariate analysis included age, gender, etiology, AFP, Child-Pugh class, MELD, alanine aminotransferase (ALT), alkaline phosphatase, bilirubin, albumin, ascites, metastasis, portal vein thrombosis, oesophageal varices, effects related to VEGF inhibition: rash, arterial hypertension, bleeding, and hand-foot syndrome (HFS). To detect factors independently related to TTP, multivariate analysis by Cox’s model was done. Results: We treated 101 patients (median age 67 years; 81 males; 98 cirrhotics; Child A/B: 79/19; 55 macrovascular invasion; 39 extrahepatic spread). Median therapy duration was 4 (range 1-16) months. Median OS was 10 (95% CI 4.5-15.5) months. TTP was 9 (95%CI 3.7-14.3) months. Complete/partial response occurred in 21% of patients and stable disease in 19%. At univariate analysis, the variables significantly related to TTP were: female sex (14 months vs 6 months, p=.05), no portal thrombosis (13 months vs 6 months, p=.04), ALT =60UI (15 months vs 6 months, p=.02), no ascites (11 months vs 2 months, p=.003), and occurrence of HFS (16 months vs 5 months, p

Published
2011
Full Text
View/download PDF

45. P.1.54: TREATMENT OF THE 'UNCOMMON' HCV GENOTYPE 4 INFECTION RECURRENCE AFTER LIVER TRANSPLANTATION. AN 'AISF RECOLT-C' STUDY

Author

M. Marino, F.R. Ponziani, Valerio Giannelli, M. Rendina, D. Di Paolo, L. Miglioresi, Maria Francesca Donato, Pierluigi Toniutto, A. Milani, E. De Martin, Raffaella Viganò, Alessandro Gasbarrini, Stefano Fagiuoli, M.C. Morelli, Maurizio Pompili, and Luisa Pasulo

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, medicine.medical_treatment, Genotype, Gastroenterology, Medicine, Liver transplantation, business
Published
2011
Full Text
View/download PDF

46. 427 TREATMENT OF HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: GENDER ISSUE ON THERAPY OUTCOME

Author

Stefano Fagiuoli, Cristina Lucidi, Raffaella Viganò, D. Di Paolo, M. Rendina, E. De Martin, Pierluigi Toniutto, Michela Giusto, Valerio Giannelli, Francesco Donato, Rosa Maria Iemmolo, M.C. Morelli, L. Miglioresi, Maurizio Pompili, Luisa Pasulo, Manuela Merli, and F.R. Ponziani

Subjects
Therapy Outcome, medicine.medical_specialty, Hepatology, business.industry, General surgery, medicine.medical_treatment, Hepatitis C, Liver transplantation, medicine.disease, University hospital, Gastroenterology, Internal medicine, medicine, business
Abstract

427 TREATMENT OF HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: GENDER ISSUE ON THERAPY OUTCOME V. Giannelli, C. Lucidi, M. Giusto, F.R. Ponziani, M. Pompili, R. Vigano, R.M. Iemmolo, F.M. Donato, M. Rendina, P. Toniutto, L. Pasulo, S. Fagiuoli, M.C. Morelli, E. de Martin, L. Miglioresi, D. di Paolo, M. Merli, RECOLT-C. Sapienza University of Rome, Cattolica Sacro Cuore, Niguarda Ca’Granda Hospital, Rome, Modena University, Modena, Maggiore Hospital, Milan, Bari University, Bari, Udine University, Udine, Bergamo University, Bergamo, Sant’Orsola Malpighi Hospital, Bologna, Padua University Hospital, Padua, San Camillo-Spallanzani Hospital, Tor Vergata University Hospital, Rome, Italy E-mail: mr_valegiann84@hotmail.it

Published
2011
Full Text
View/download PDF

47. 561 BEST MATCHING FOR HCV GENOTYPE 1 LIVER TRANSPLANT RECIPIENTS IS PREDICTED BY HCV1-STAR. A STUDY FROM AISF RECOLT-C DATABASE

Author

F.R. Ponziani, Raffaella Viganò, Valerio Giannelli, A. Milani, Alessandro Gasbarrini, L. Miglioresi, Maurizio Pompili, Rosa Maria Iemmolo, D. Di Paolo, Matteo Cescon, Stefano Fagiuoli, Pierluigi Toniutto, Maria Francesca Donato, M. Rendina, Luisa Pasulo, and E. De Martin

Subjects
Oncology, medicine.medical_specialty, Hepatology, Hcv genotype 1, business.industry, Internal medicine, medicine, Star (graph theory), Best matching, business
Published
2011
Full Text
View/download PDF

48. 551 DONOR-RELATED CHARACTERISTICS AS PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE TO ANTIVIRAL THERAPY IN RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION

Author

G.E. Gerunda, Ezio Fornasiere, M. Marino, Roberto Montalti, Raffaella Viganò, D. Di Paolo, Valerio Giannelli, L. Migliorasi, F.R. Ponziani, Stefano Fagiuoli, Maria Francesca Donato, E. De Martin, M.C. Morelli, Rosa Maria Iemmolo, and M. Rendina

Subjects
medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Virologic response, Internal medicine, medicine, Antiviral therapy, Liver transplantation, Recurrent hepatitis, business, Gastroenterology
Published
2011
Full Text
View/download PDF

49. 532 POOR ADHERENCE TO PEGYLATED-INTERFERON AND RIBAVIRIN IS A MAJOR CONCERN IN THE TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: EVIDENCE FROM THE RECOLT-C GROUP

Author

G. Tisone, Matteo Cescon, Stefano Fagiuoli, L. Miglioresi, M.F. Ponato, D. Di Paolo, M. Rendina, E. De Martin, F.R. Ponziani, Raffaella Viganò, Rosa Maria Iemmolo, Mario Angelico, Pierluigi Toniutto, and Manuela Merli

Subjects
medicine.medical_specialty, Hepatology, business.industry, Ribavirin, medicine.medical_treatment, Liver transplantation, Gastroenterology, Virology, Poor adherence, chemistry.chemical_compound, chemistry, Pegylated interferon, Internal medicine, Medicine, Recurrent hepatitis, business, medicine.drug
Published
2011
Full Text
View/download PDF

50. 578 IS THE PRIMARY IMMUNOSUPPRESSIVE DRUG (CYCLOSPORIN A OR TACROLIMUS) PLAYING A ROLE ON THE RESPONSE TO ANTIVIRAL TREATMENT FOR POST-TRANSPLANT HCV RECURRENCE?

Author

D. Di Paolo, F.R. Ponziani, Pierluigi Toniutto, Raffaella Viganò, Valerio Giannelli, L. Miglioresi, Stefano Fagiuoli, Matteo Cescon, Maria Francesca Donato, M. Marino, M. Rendina, V. Vero, E. De Martin, Marco Senzolo, and Luisa Pasulo

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Hcv recurrence, Post transplant, Tacrolimus, Immunosuppressive drug, Cyclosporin a, Internal medicine, Medicine, Antiviral treatment, business
Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results